Fig. 1: Patient outcomes based on ex vivo venetoclax testing.
From: Venetoclax ex vivo functional profiling predicts improved progression-free survival
Pre-treatment bone marrow aspirates were tested ex vivo for venetoclax sensitivity as described previously [3]. Briefly, buffy coat cells were treated with increasing concentrations of venetoclax for 24 h and then assessed for apoptosis by annexin V staining to determine an IC50. An IC50 of less than 100 nM was considered sensitive, while an IC50 of greater than 100 nM was considered resistant. A Overall response rate for patients with sensitive vs. resistant ex vivo testing. B PFS and C OS of sensitive and resistant patients. D Receiver operating curve for ex vivo testing.
